Biomarkers are an invaluable guide for optimising treatment in many diseases. Which biomarkers should we be utilising in colorectal cancer? When should we use them? And what impact do they have on treatment choices? The following e-learning course includes expert opinion on the latest answers to these important questions.

Should the site of colorectal cancer impact on treatment decisions? Are there meaningful differences in outcomes between patients depending on the site of their tumour? What should we do with the information we have available? Click through to learn more about this ongoing debate from our panel of experts.

The length of treatment for colorectal cancer (CRC) patients in the adjuvant setting is a controversial topic. Recent studies have compared the outcomes for patients receiving adjuvant therapy with FOLFOX or CAPOX for 3 or for 6 months. What should be the recommended length of treatment for CRC patients in the adjuvant setting? Do recent data support a 3-month or 6-month duration? The following e-learning course includes expert opinions on the latest answers to these important questions.

Conventional first-line treatment continues until disease progression or intolerable toxicities. Today, the majority of patients discontinue due to side effects of chemotherapy. Recent studies have investigated the place of intermittent and continuous treatment regimens in patients with mCRC. Which is the best treatment approach? What impact do they have on potential outcomes? And which patients would best benefit from each approach? The following e-learning course includes expert opinion on the latest answers to these important questions.

This e-learning demonstrates what you need to explain to your patients requiring 3rd-line treatment of mCRC and how to confidently communicate these messages for an optimal physician-patient interaction.

Ultimately, success is both parties being satisfied with the decision-making process and with the decision that is made.

While often thought of as a subgroup of colorectal cancer (CRC) patients, the elderly make up three out of every five cases. What does this mean for treatment, how should we assess their needs, and what should we do for those not fit for treatment? Click through for more discussion on the management of elderly and unfit CRC patients.

Experts provide opposing perspectives on the management of later-line CRC on treatment sequencing and flexible dosing of regorafenib.

Note that the views presented do not reflect the Experts’ own opinions but are intended to represent opposing perspectives on the topic of discussion.

EACCME Accreditation

COR2ED Checkpoint, made available on and organized by COR2ED, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.

Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

Information on the process to convert EACCME credit to AMA credit can be found at